Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-FR Version v9-FR
Language French French
Date Updated 2022-09-21 2022-09-21
Drug Identification Number 00533688 00533688
Brand name TOBRAMYCIN FOR INJECTION TOBRAMYCIN FOR INJECTION
Common or Proper name Tobramycin for Injection Tobramycin for Injection
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients TOBRAMYCIN TOBRAMYCIN
Strength(s) 1.2G 1.2G
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 50 mL 50 mL
ATC code J01GB J01GB
ATC description AMINOGLYCOSIDE ANTIBACTERIALS AMINOGLYCOSIDE ANTIBACTERIALS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2022-07-01 2022-07-01
Estimated end date 2022-09-20 2022-09-20
Actual end date 2022-09-20 2022-09-20
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments We regret to advise that our Tobramycin for Injection 1.2 g PBP Vial 50 mL will be encountering a supply interruption effective July 1, 2022 until September 20, 2022. We regret to advise that our Tobramycin for Injection 1.2 g PBP Vial 50 mL will be encountering a supply interruption effective July 1, 2022 until September 20, 2022.
Health Canada comments